Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.…
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
Radiopharm Theranostics (NASDAQ: RADX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 0.6304 USD on 20 November 2026, down 86.4% over 52 weeks. Its 52-week range is 0.6300 USD to 16.25 USD, and it trades at the bottom of that range.
Its market capitalisation is 9.90M USD.
Radiopharm Theranostics reports return on equity of -230.7%, an operating margin of -411.6% and revenue down 36.9% year over year.
It holds more cash than debt, a net cash position of 4.14M AUD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.